LAVA Therapeutics N.V.
Latest round
- Series C
Last raised
- Sep 2020
Total raised
- $103M
Investors
- 8
About LAVA Therapeutics N.V.
V. specializes in cancer immunotherapy.LAVA Therapeutics specializes in innovative cancer therapies through its Gammabody® platform, which produces bispecific gamma delta T cell engagers.9Vd2 T cells, enhancing tumor recognition and selective cell killing.88 mn.LAVA Therapeutics is strategically positioned for future growth through the development of new products in its Gammabody® platform, which are anticipated to launch within the next few years. The company plans to expand its market reach into North America and Europe by 2025.
Who invested in LAVA Therapeutics N.V.
8 investors across 2 rounds
See all investors in LAVA Therapeutics N.V.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LAVA Therapeutics N.V.
Who invested in LAVA Therapeutics N.V.?
LAVA Therapeutics N.V. has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LAVA Therapeutics N.V. raised?
LAVA Therapeutics N.V. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did LAVA Therapeutics N.V. last raise money?
LAVA Therapeutics N.V.'s most recent round on record is a Series C, in Sep 2020.
What does LAVA Therapeutics N.V. do?
LAVA Therapeutics N.V. is a biotechnology company.
Where is LAVA Therapeutics N.V. headquartered?
LAVA Therapeutics N.V. is headquartered in Utrecht, Netherlands.
Which VCs invest in companies like LAVA Therapeutics N.V.?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at LAVA Therapeutics N.V.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like LAVA Therapeutics N.V.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.